Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma

Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma

During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.

Dose Modification and Premedications Aid in Tolerability of NDMM Therapy

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants how they manage toxicity of transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Induction and Transplant Outcomes Improve With Quadruplet NDMM Regimen

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Benefit of Dara-Rd Maintained Across Age Groups in Transplant-Ineligible NDMM

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the SWOG S0777 and MAIA trials in transplant-ineligible newly diagnosed multiple myeloma in the second article of a 2-part series.

Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Quadruplet Trials Form New Standard in Transplant-Eligible Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.

Trials Shed Light on Transplant and Maintenance in NDMM

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.

Approaches to Manage Frontline Therapy for Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.

Supportive Care for Maintenance in Transplant-Ineligible Multiple Myeloma

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.

Adverse Event Management in Transplant-Eligible Multiple Myeloma

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MBBS, discussed with participants the tolerability and optimal use of therapies for newly-diagnosed multiple myeloma.

The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma

During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.

Using Frontline Quadruplet Therapy for Transplant-Eligible Multiple Myeloma

During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.

Multiple Myeloma Goals and Risk Factors for Triplet Vs Quadruplet Therapy

During a live virtual event, Caitlin Costello, MD, discussed the rationale for choosing a triplet or quadruplet regimen for patients with transplant-eligible newly diagnosed multiple myeloma.

Part 2: Using Depth of Response and MRD as Goals for Multiple Myeloma

During a live virtual event, Douglas Sborov, MD, MS, discussed the most important goals for treatment and the use of minimal residual disease assessment for a patient with transplant-eligible multiple myeloma.

Part 1: Debating Primary Therapy for Transplant-Eligible Multiple Myeloma

During a live virtual event, Douglas Sborov, MD, MS, discussed the possible treatment regimens for a patient with newly diagnosed multiple myeloma who is eligible for stem cell transplant.

Part 2: Recommending Triplet and Quadruplet Therapies for Multiple Myeloma

During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.

Part 1: Assessing Transplant Eligibility Following Treatment for Multiple Myeloma

During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.

Part 2: Daratumumab Shows Greater PFS Benefit Early On in Multiple Myeloma

During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.

Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma

During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.